April 16, 2024
TOPLINE: An analysis of molecular-targeted cancer drug therapies recently approved in the United States found that fewer than one third demonstrated substantial clinical benefits at the […]
April 15, 2024
In recent years, innovative use of bispecific antibodies and CAR T-cell therapy has ushered in an era when many patients with relapsed/refractory acute lymphoblastic leukemia (ALL) […]
April 15, 2024
SAN DIEGO — Monitoring a patient’s circulating tumor DNA (ctDNA) can provide valuable insights on early response to targeted therapies among patients with HER2-positive cancers. This […]
April 15, 2024
TOPLINE: Omitting axillary lymph node dissection does not increase the risk for recurrence or compromise 5-year overall survival outcomes in patients with early-stage, node-negative breast cancer […]
April 12, 2024
TOPLINE: A recent survey highlighted ethical concerns US oncologists have about using artificial intelligence (AI) to help make cancer treatment decisions and revealed some contradictory views […]
April 12, 2024
Early data suggested that several new multicancer early detection (MCED) tests in development show promise for identifying cancers that lack routine screening options. Analyses presented during […]
April 12, 2024
SAN DIEGO — A new blood test that combines cell-free DNA fragmentomes and protein biomarkers to screen for ovarian cancer shows promising results, according to an […]
April 11, 2024
TOPLINE: New estimates show that patient enrollment in cancer clinical trials focused on treatments is about twice as high now compared with past estimates, with rates […]
April 11, 2024
Multitarget stool-based tests are showing promise for colorectal cancer (CRC) screening in average-risk individuals and could edge out the current standard fecal immunochemical test (FIT). These […]